Non-invasive white cell count prototype
Several chemotherapy regimens yield better survival when administered with higher frequency and dose. However, because chemotherapy administration can only be given when there is an adequate white blood cell count (to confer the ability to fight infection) the typical treatment is conservatively set at a lower frequency and dose. This project is to develop a noninvasive white blood cell test that enables much more frequent measurement thereby enabling physicians to personalize chemotherapy planning and improve the efficacy and safety of the overall treatment.
The technology from this project was spun out into a startup company, Leuko Labs.